Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 6/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 4/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | BCL6 | P41182 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23388552 | 0.82 | MAPK3 (0.63) | MAPK1MAPK3CDK7CDK9 | |
| SCHEMBL23408957 | 0.77 | MAPK1 (0.53) | MAPK1MAPK3CTSCCDK7CDK9 | |
| SCHEMBL23409081 | 0.77 | MAPK1 (0.52) | MAPK1MAPK3CTSCCDK7CDK9 | |
| SCHEMBL25068865 | 0.75 | MAPK1 (0.51) | MAPK1MAPK3CTSCCDK7CDK9 | |
| SCHEMBL28744841 | 0.72 | MAPK1 (0.56) | MAPK1MAPK3CTSCCDK7CDK9 | |
| SCHEMBL29499572 | 0.72 | MAPK1 (0.56) | MAPK1MAPK3CTSCCDK7CDK9 | |
| SCHEMBL23408943 | 0.66 | MAPK1 (0.67) | MAPK1MAPK3CDK7CDK9 | |
| SCHEMBL23409118 | 0.66 | MAPK3 (0.67) | MAPK1MAPK3CDK7CDK9 | |
| SCHEMBL25068863 | 0.66 | MAPK3 (0.66) | MAPK1MAPK3CDK7CDK9 | |
| SCHEMBL7092722 | 0.66 | EGFR (0.77) | BCL6EGFRERBB2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2021099842-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC. (CA) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | MAPK1 4417/4885MAPK3 3458/4885CTSC 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.